- Tuesday, 30 April 2019
Article from STOCKHEAD
Regenerative medicine company Regeneus has secured seasoned industry leaders to its board as it looks to make bigger noise overseas.
- Wednesday, 30 January 2019
Interview with Proactive Investors
Leo Lee, the newly-appointed CEO of Regeneus Ltd (ASX:RGS), speaks to Proactive Investors about the Australian clinical-stage regenerative medicine company's operations, and the wider scientific field.
- Wednesday, 5 September 2018
Regeneus has revised expected timing of an osteoarthritis (OA) clinical development licence deal for Progenza in Japan to Q4 CY18 (vs Q218); it is currently in active discussions with several parties. A licence deal would trigger a US$5m milestone payment from partner AGC and would effectively see Progenza commence a Phase II trial in knee OA in Japan.
- Monday, 30 July 2018
Cancer vaccine trial meets primary endpoint of safety with promising signs of immune responseKey points
- Primary endpoint of safety and tolerability met
- Immune response detected at all dose levels